|1.||Salvati, Mark E: 2 articles (08/2015 - 08/2009)|
|2.||Gottardis, Marco: 2 articles (08/2015 - 02/2011)|
|3.||Balog, Aaron: 2 articles (08/2015 - 08/2009)|
|4.||Dell-John, Janet: 2 articles (08/2015 - 08/2009)|
|5.||Shan, Weifang: 2 articles (08/2015 - 08/2009)|
|6.||Schweizer, Liang: 2 articles (08/2015 - 08/2009)|
|7.||Martin, Gregory S: 1 article (08/2015)|
|8.||Nation, Andrew: 1 article (08/2015)|
|9.||Gougoutas, Jack: 1 article (08/2015)|
|10.||Trainor, George: 1 article (08/2015)|
|1.||Prostatic Neoplasms (Prostate Cancer)
08/15/2009 - "Overall, these data highlight that the unique preclinical profile of BMS-641988 may provide additional understanding for the hormonal treatment of prostate cancer."
02/15/2011 - "A first-in-man phase I study was conducted to define the safety and tolerability of oral BMS-641988 in patients with castration-resistant prostate cancer (CRPC). "
02/15/2011 - "Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer."
08/13/2015 - "BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. "
08/13/2015 - "Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer."
08/15/2009 - "Furthermore, BMS-641988 was efficacious in CWR-22-BMSLD1 tumors initially refractory to treatment with bicalutamide. "
08/15/2009 - "In the CWR-22-BMSLD1 human prostate cancer xenograft model, BMS-641988 showed increased efficacy over bicalutamide (average percent tumor growth inhibition >90% versus <50%), even at exposure levels of bicalutamide 3-fold greater than what can be attained in humans. "
02/15/2011 - "Although the clinical outcomes of predominantly stable disease and partial agonism were similar to what was observed in the preclinical evaluation of the compound, the limited antitumor activity of BMS-641988 at therapeutic dose levels coupled with an episode of seizure activity led to study closure."
|2.||Androgen Receptors (Androgen Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)